6.06
Amicus Therapeutics Inc stock is traded at $6.06, with a volume of 3.51M.
It is down -3.50% in the last 24 hours and up +7.07% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$6.28
Open:
$6.27
24h Volume:
3.51M
Relative Volume:
0.71
Market Cap:
$1.87B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-17.82
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
+1.68%
1M Performance:
+7.07%
6M Performance:
-36.94%
1Y Performance:
-40.94%
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
FOLD
Amicus Therapeutics Inc
|
6.06 | 1.93B | 493.67M | -104.69M | -31.51M | -0.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-06-24 | Initiated | Jefferies | Buy |
May-30-24 | Initiated | Wells Fargo | Overweight |
May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
Apr-13-22 | Resumed | Goldman | Neutral |
Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Nov-15-21 | Upgrade | Stifel | Hold → Buy |
Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
Jul-19-21 | Resumed | BTIG Research | Buy |
May-27-21 | Initiated | Needham | Hold |
May-21-21 | Initiated | UBS | Buy |
Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-02-21 | Initiated | Stifel | Hold |
Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
Nov-11-20 | Initiated | Berenberg | Hold |
Jun-17-20 | Initiated | BTIG Research | Buy |
Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
Jun-17-19 | Initiated | H.C. Wainwright | Buy |
Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
Apr-05-19 | Initiated | Janney | Buy |
Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
Oct-29-18 | Initiated | Citigroup | Neutral |
Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Oct-06-17 | Resumed | Goldman | Neutral |
Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
May-18-16 | Initiated | BofA/Merrill | Buy |
Apr-14-16 | Initiated | Robert W. Baird | Neutral |
Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Legato Capital Management LLC - MarketBeat
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - Insider Monkey
Amicus Therapeutics Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - PrintWeekIndia
How Amicus Therapeutics Inc. stock reacts to Fed policy changesFree Investment Portfolio Suggestions - jammulinksnews.com
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Amicus Therapeutics (FOLD) Expected to Announce Earnings on Thursday - MarketBeat
What drives Amicus Therapeutics Inc. stock priceExceptional profit margins - Autocar Professional
Edgestream Partners L.P. Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
What analysts say about Amicus Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com
Published on: 2025-07-23 00:04:03 - jammulinksnews.com
Is Amicus Therapeutics Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewswire
Amicus Therapeutics Sets Date for Q2 Earnings: Key Updates Expected from Rare Disease Pipeline - Stock Titan
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by Morgan Stanley - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpWhat's Next? - MarketBeat
Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda - MSN
Amicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switching - MSN
Amicus stock gains as Morgan Stanley upgrades (FOLD:NASDAQ) - Seeking Alpha
Amicus Therapeutics: A Biotech Buy with Legal, Product, and Market Catalysts - AInvest
Amicus Therapeutics (FOLD) Soars 10.05% on Japan Approval - AInvest
Rice Hall James & Associates LLC Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics stock upgraded to Overweight by Morgan Stanley on IP strength - Investing.com Canada
Stephens Investment Management Group LLC Makes New $5 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
10 Best Small-Cap Stocks to Buy According to Billionaires - Insider Monkey
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):